Cyclobutyl Sulfone Selective Gamma Secretase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current γ-secretase inhibitors for treating Alzheimer's disease often cause Notch-related toxicities due to non-selective inhibition of APP and Notch processing, leading to gastrointestinal issues and other complications.
Innovation Solution
Development of novel cyclobutyl sulfone derivatives that specifically inhibit APP processing by γ-secretase while sparing the Notch signaling pathway, minimizing Notch inhibition-mediated toxicities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If γ-secretase inhibitors are used to treat Alzheimer's disease, then APP processing is inhibited and Aβ production is reduced, but Notch processing is also inhibited causing gastrointestinal toxicities and other complications
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (cyclobutyl sulfone core with particular substituent patterns) that create selective interaction with the γ-secretase active site. This allows the inhibitor to bind preferentially when APP is positioned in the catalytic cleft, while sparing Notch processing through subtle differences in substrate positioning and binding kinetics, thereby achieving therapeutic efficacy without Notch-related toxicities
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types (fluoro, chloro, cyano groups), positions, and steric characteristics on the cyclobutyl sulfone scaffold. These parameter modifications tune the compound's selectivity profile, optimizing the balance between APP inhibition potency and Notch sparing to eliminate gastrointestinal toxicities while maintaining therapeutic efficacy
2Quantity of substance
If non-selective γ-secretase inhibitors are used, then APP processing is inhibited, but Notch signaling pathway is also blocked leading to gastrointestinal issues
Solution Approach 1:
The patent applies segmentation by dividing the γ-secretase substrate recognition interface into distinct functional regions. The cyclobutyl sulfone core targets the catalytic aspartates for APP processing inhibition, while specific substituent patterns on the phenyl and heterocyclic rings interact with substrate-specific regions that differentiate APP from Notch substrates. This segmented binding strategy achieves selective Aβ production inhibition while preserving Notch signaling and avoiding gastrointestinal toxicities
Data Source
AI summary
The invention encompasses a novel class of cyclobutyl sulfone derivatives which inhibit the processing of APP by the putative γ-secretase while sparing Notch signaling pathway, and thus are useful in the treatment or prevention of Alzheimer's disease without the development of Notch inhibition mediated gastrointestinal issues. Pharmaceutical compositions and methods of use are also included.